28
Participants
Start Date
August 24, 2021
Primary Completion Date
March 2, 2024
Study Completion Date
March 2, 2024
cryoablation
Cryoablation treatment starts at day 0.
Sintilimab
Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
lenvatinib
Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER